David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his stake in the company with a recent purchase of common stock. According to a ...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) filed a Form 8-K with the United States Securities and Exchange Commission (SEC). In this filing, Processa Pharmaceuticals disclosed that a copy of a slide ...

Processa Pharmaceuticals Inc. (PCSA) stock has tumbled to a 52-week low, touching down at $0.65, with InvestingPro data showing concerning financial health indicators and a weak overall score of 1.55.

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, were $5 million (excluding any proceeds that may be received upon the ...

HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

Processa Pharmaceuticals, Inc. announced the pricing of a public offering aimed at raising approximately $5 million, with participation from its CEO, board members, and institutional investors.

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be $5 million (excluding any proceeds that may be ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a ...

Processa Pharmaceuticals, Inc. HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical ...

HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical ...